About Vasopressin V2 receptor
Vasopressin V2 receptor (AVPR2) is a protein
from Homo sapiens identified by UniProt accession
P30518, 371 residues long.
MolForge cross-references it against 0 known binders and
290 disease associations.
Target properties
| Protein name | Vasopressin V2 receptor |
| UniProt accession | P30518 |
| Gene | AVPR2 |
| Organism | Homo sapiens |
| Length | 371 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (12)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (290)
Diseases linked to this target (Open Targets).
- nephrogenic syndrome of inappropriate antidiuresis · score 0.74
- nephrogenic diabetes insipidus · score 0.72
- hemorrhage · score 0.59
- enuresis · score 0.59
- Hyponatremia · score 0.59
- diabetes insipidus · score 0.58
- heart failure · score 0.58
- Autosomal dominant polycystic kidney disease · score 0.57
- Nasal congestion · score 0.56
- septic shock · score 0.56
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P30518-F1 | alphafold | PREDICTED | 76.02 | — |
Amino-acid sequence (371 residues)
MLMASTTSAV PGHPSLPSLP SNSSQERPLD TRDPLLARAE LALLSIVFVA VALSNGLVLA ALARRGRRGH WAPIHVFIGH LCLADLAVAL FQVLPQLAWK ATDRFRGPDA LCRAVKYLQM VGMYASSYMI LAMTLDRHRA ICRPMLAYRH GSGAHWNRPV LVAWAFSLLL SLPQLFIFAQ RNVEGGSGVT DCWACFAEPW GRRTYVTWIA LMVFVAPTLG IAACQVLIFR EIHASLVPGP SERPGGRRRG RRTGSPGEGA HVSAAVAKTV RMTLVIVVVY VLCWAPFFLV QLWAAWDPEA PLEGAPFVLL MLLASLNSCT NPWIYASFSS SVSSELRSLL CCARGRTPPS LGPQDESCTT ASSSLAKDTS S
Explore Vasopressin V2 receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets